GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
The Mycophenolate Pregnancy Registry
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT01733082
- Locations
- 🇺🇸
Quintiles Outcome, Cambridge, Massachusetts, United States
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT01723826
- Locations
- 🇨🇦
Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Margolin Brain Institute, Fresno, California, United States
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT01712334
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01711762
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT01691898
- Locations
- 🇮🇹
Azienda Ospedale San Giovanni, Torino, Piemonte, Italy
🇺🇸Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States
🇨🇦McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01685892
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States
🇺🇸Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01671904
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
🇫🇷Hopital Saint Eloi, Montpellier, France
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT01662063
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01656642
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT01652482